Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model
Open Access
- 15 May 2012
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 106 (12) , 1945-1952
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 43 references indexed in Scilit:
- Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: Correlation with intravesical recurrence following transurethral resectionUrologic Oncology: Seminars and Original Investigations, 2011
- Induction of Clusterin by AKT—Role in Cytoprotection against Docetaxel in Prostate Tumor CellsMolecular Cancer Therapeutics, 2010
- Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced CancerClinical Cancer Research, 2010
- Clusterin Facilitates COMMD1 and I-κB Degradation to Enhance NF-κB Activity in Prostate Cancer CellsMolecular Cancer Research, 2010
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agentsBJU International, 2006
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancerNature Reviews Drug Discovery, 2006
- The inhibition of angiogenesis by antisense oligonucleotides to clusterinAngiogenesis, 2005
- Clusterin inhibits apoptosis by interacting with activated BaxNature Cell Biology, 2005
- Introduction of Clusterin Gene into Human Renal Cell Carcinoma Cells Enhances Their Resistance to Cytotoxic Chemotherapy through Inhibition of Apoptosis both in vitro and in vivoJapanese Journal of Cancer Research, 2001